AustralieFrV1, Main, Exploration, bibRecord, 00B750

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease

Identifieur interne : 00B750 ( Main/Exploration ); précédent : 00B749; suivant : 00B751

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease

Auteurs : Serge Gauthier [Canada] ; Howard Feldman [Canada] ; Jane Hecker [Australie] ; Bruno Vellas [France] ; David Ames [Australie] ; Ponni Subbiah [États-Unis] ; Edward Whalen [États-Unis] ; Birol Emir [États-Unis]

Source :

International psychogeriatrics [ 1041-6102 ] ; 2002.

RBID : Pascal:03-0199610

Descripteurs français

Pascal (Inist)
- Démence Alzheimer, Donépézil, Trouble comportement, Psychotrope, Chimiothérapie, Trouble psychiatrique, Efficacité traitement, Personne âgée, Pipéridine dérivé.
Wicri :
- topic : Personne âgée.

English descriptors

KwdEn :
- Alzheimer disease, Behavioral disorder, Chemotherapy, Donepezil, Elderly, Mental disorder, Piperidine derivatives, Psychotropic, Treatment efficiency.

Abstract

Objective: This subanalysis of a large, double-blind, placebo-controlled trial examined the prevalence of behavioral symptoms in moderate to severe Alzheimer's disease (AD), and the effect of treatment with donepezil. Methods: Two hundred ninety patients with moderate to severe AD (standardized Mini-Mental State Examination scores 5-17) were randomized to receive 24 weeks of once-daily doses of donepezil 5 mg/day for 28 days, and 10 mg/day thereafter per the clinician's judgment (n = 144), or placebo (n = 146). The outcome measure of interest was the 12-item Neuropsychiatric Inventory (NPI). Results: Baseline demographics were similar between the treatment groups. Least squares mean (± SE) baseline NPI 12-item total scores were 19.55 ± 1.48 and 19.30 ± 1.45, respectively. At baseline, the most common symptoms were apathy/indifference (67%), aberrant motor behavior (53%), depression/dysphoria (52%), anxiety (49%), and agitation/aggression (45%). NPI individual item change from baseline scores at Week 24 using a last observation carried forward (LOCF) analysis showed benefits with donepezil treatment compared with placebo for all items, with significant treatment differences for depression/dysphoria, anxiety, and apathy/indifference (p <.05). Symptoms present at baseline that improved significantly for donepezil- compared with placebo-treated patients at Week 24 LOCF included anxiety, apathy/indifference, and irritability/lability (p <.05). When patients who were not receiving psychoactive medications at baseline were analyzed separately, significant improvements in NPI 12-item total score were observed with donepezil compared with placebo at most visits and at Week 24 LOCF (p <.05). Conclusions: Behavioral symptoms of the magnitude observed in this moderate to severe AD population improved with donepezil.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 005397
to stream PascalFrancis, to step Curation: 000D29
to stream PascalFrancis, to step Checkpoint: 005453
to stream Main, to step Merge: 00C574
to stream Main, to step Curation: 00B750

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease</title>
<author><name sortKey="Gauthier, Serge" sort="Gauthier, Serge" uniqKey="Gauthier S" first="Serge" last="Gauthier">Serge Gauthier</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Alzheimer's Disease Research Unit, McGill Centre for Studies in Aging</s1>
<s2>Verdun</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Verdun</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Feldman, Howard" sort="Feldman, Howard" uniqKey="Feldman H" first="Howard" last="Feldman">Howard Feldman</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Neurology, UBC Hospital, Clinic for Alzheimer's Disease and Related Disorders</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hecker, Jane" sort="Hecker, Jane" uniqKey="Hecker J" first="Jane" last="Hecker">Jane Hecker</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Rehabilitation and Aged Care, Repatriation General Hospital</s1>
<s2>Daw Park</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Daw Park</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Vellas, Bruno" sort="Vellas, Bruno" uniqKey="Vellas B" first="Bruno" last="Vellas">Bruno Vellas</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Toulouse University Alzheimer's Center</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ames, David" sort="Ames, David" uniqKey="Ames D" first="David" last="Ames">David Ames</name>
<affiliation wicri:level="4"><inist:fA14 i1="05"><s1>University of Melbourne, Department of Psychiatry, Royal Melbourne Hospital</s1>
<s2>Parkville</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Parkville</wicri:noRegion>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Subbiah, Ponni" sort="Subbiah, Ponni" uniqKey="Subbiah P" first="Ponni" last="Subbiah">Ponni Subbiah</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>CNS, Pfizer Pharmaceuticals Group, Pfizer Inc</s1>
<s2> New York. New York.</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion> New York. New York.</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Whalen, Edward" sort="Whalen, Edward" uniqKey="Whalen E" first="Edward" last="Whalen">Edward Whalen</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1> Biometrics Department, Pfizer Pharmaceuticals Group, Pfizer Inc.</s1>
<s2>New York. New York</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>New York. New York</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Emir, Birol" sort="Emir, Birol" uniqKey="Emir B" first="Birol" last="Emir">Birol Emir</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Clinical Data Operations, Pfizer Pharmaceuticals Group, Pfizer Inc.,</s1>
<s2> New York. New York</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion> New York. New York</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0199610</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 03-0199610 INIST</idno>
<idno type="RBID">Pascal:03-0199610</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">005397</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000D29</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">005453</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">005453</idno>
<idno type="wicri:doubleKey">1041-6102:2002:Gauthier S:efficacy:of:donepezil</idno>
<idno type="wicri:Area/Main/Merge">00C574</idno>
<idno type="wicri:Area/Main/Curation">00B750</idno>
<idno type="wicri:Area/Main/Exploration">00B750</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease</title>
<author><name sortKey="Gauthier, Serge" sort="Gauthier, Serge" uniqKey="Gauthier S" first="Serge" last="Gauthier">Serge Gauthier</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Alzheimer's Disease Research Unit, McGill Centre for Studies in Aging</s1>
<s2>Verdun</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Verdun</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Feldman, Howard" sort="Feldman, Howard" uniqKey="Feldman H" first="Howard" last="Feldman">Howard Feldman</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Neurology, UBC Hospital, Clinic for Alzheimer's Disease and Related Disorders</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hecker, Jane" sort="Hecker, Jane" uniqKey="Hecker J" first="Jane" last="Hecker">Jane Hecker</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Rehabilitation and Aged Care, Repatriation General Hospital</s1>
<s2>Daw Park</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Daw Park</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Vellas, Bruno" sort="Vellas, Bruno" uniqKey="Vellas B" first="Bruno" last="Vellas">Bruno Vellas</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Toulouse University Alzheimer's Center</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ames, David" sort="Ames, David" uniqKey="Ames D" first="David" last="Ames">David Ames</name>
<affiliation wicri:level="4"><inist:fA14 i1="05"><s1>University of Melbourne, Department of Psychiatry, Royal Melbourne Hospital</s1>
<s2>Parkville</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Parkville</wicri:noRegion>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Subbiah, Ponni" sort="Subbiah, Ponni" uniqKey="Subbiah P" first="Ponni" last="Subbiah">Ponni Subbiah</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>CNS, Pfizer Pharmaceuticals Group, Pfizer Inc</s1>
<s2> New York. New York.</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion> New York. New York.</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Whalen, Edward" sort="Whalen, Edward" uniqKey="Whalen E" first="Edward" last="Whalen">Edward Whalen</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1> Biometrics Department, Pfizer Pharmaceuticals Group, Pfizer Inc.</s1>
<s2>New York. New York</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>New York. New York</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Emir, Birol" sort="Emir, Birol" uniqKey="Emir B" first="Birol" last="Emir">Birol Emir</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Clinical Data Operations, Pfizer Pharmaceuticals Group, Pfizer Inc.,</s1>
<s2> New York. New York</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion> New York. New York</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">International psychogeriatrics</title>
<title level="j" type="abbreviated">Int. psychogeriatr.</title>
<idno type="ISSN">1041-6102</idno>
<imprint><date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">International psychogeriatrics</title>
<title level="j" type="abbreviated">Int. psychogeriatr.</title>
<idno type="ISSN">1041-6102</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer disease</term>
<term>Behavioral disorder</term>
<term>Chemotherapy</term>
<term>Donepezil</term>
<term>Elderly</term>
<term>Mental disorder</term>
<term>Piperidine derivatives</term>
<term>Psychotropic</term>
<term>Treatment efficiency</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Démence Alzheimer</term>
<term>Donépézil</term>
<term>Trouble comportement</term>
<term>Psychotrope</term>
<term>Chimiothérapie</term>
<term>Trouble psychiatrique</term>
<term>Efficacité traitement</term>
<term>Personne âgée</term>
<term>Pipéridine dérivé</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Personne âgée</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective: This subanalysis of a large, double-blind, placebo-controlled trial examined the prevalence of behavioral symptoms in moderate to severe Alzheimer's disease (AD), and the effect of treatment with donepezil. Methods: Two hundred ninety patients with moderate to severe AD (standardized Mini-Mental State Examination scores 5-17) were randomized to receive 24 weeks of once-daily doses of donepezil 5 mg/day for 28 days, and 10 mg/day thereafter per the clinician's judgment (n = 144), or placebo (n = 146). The outcome measure of interest was the 12-item Neuropsychiatric Inventory (NPI). Results: Baseline demographics were similar between the treatment groups. Least squares mean (± SE) baseline NPI 12-item total scores were 19.55 ± 1.48 and 19.30 ± 1.45, respectively. At baseline, the most common symptoms were apathy/indifference (67%), aberrant motor behavior (53%), depression/dysphoria (52%), anxiety (49%), and agitation/aggression (45%). NPI individual item change from baseline scores at Week 24 using a last observation carried forward (LOCF) analysis showed benefits with donepezil treatment compared with placebo for all items, with significant treatment differences for depression/dysphoria, anxiety, and apathy/indifference (p <.05). Symptoms present at baseline that improved significantly for donepezil- compared with placebo-treated patients at Week 24 LOCF included anxiety, apathy/indifference, and irritability/lability (p <.05). When patients who were not receiving psychoactive medications at baseline were analyzed separately, significant improvements in NPI 12-item total score were observed with donepezil compared with placebo at most visits and at Week 24 LOCF (p <.05). Conclusions: Behavioral symptoms of the magnitude observed in this moderate to severe AD population improved with donepezil.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>Canada</li>
<li>France</li>
<li>États-Unis</li>
</country>
<region><li>Midi-Pyrénées</li>
<li>Occitanie (région administrative)</li>
<li>Victoria (État)</li>
</region>
<settlement><li>Melbourne</li>
<li>Toulouse</li>
</settlement>
<orgName><li>Université de Melbourne</li>
</orgName>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Gauthier, Serge" sort="Gauthier, Serge" uniqKey="Gauthier S" first="Serge" last="Gauthier">Serge Gauthier</name>
</noRegion>
<name sortKey="Feldman, Howard" sort="Feldman, Howard" uniqKey="Feldman H" first="Howard" last="Feldman">Howard Feldman</name>
</country>
<country name="Australie"><noRegion><name sortKey="Hecker, Jane" sort="Hecker, Jane" uniqKey="Hecker J" first="Jane" last="Hecker">Jane Hecker</name>
</noRegion>
<name sortKey="Ames, David" sort="Ames, David" uniqKey="Ames D" first="David" last="Ames">David Ames</name>
</country>
<country name="France"><region name="Occitanie (région administrative)"><name sortKey="Vellas, Bruno" sort="Vellas, Bruno" uniqKey="Vellas B" first="Bruno" last="Vellas">Bruno Vellas</name>
</region>
</country>
<country name="États-Unis"><noRegion><name sortKey="Subbiah, Ponni" sort="Subbiah, Ponni" uniqKey="Subbiah P" first="Ponni" last="Subbiah">Ponni Subbiah</name>
</noRegion>
<name sortKey="Emir, Birol" sort="Emir, Birol" uniqKey="Emir B" first="Birol" last="Emir">Birol Emir</name>
<name sortKey="Whalen, Edward" sort="Whalen, Edward" uniqKey="Whalen E" first="Edward" last="Whalen">Edward Whalen</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00B750 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00B750 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:03-0199610
   |texte=   Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri